Shu Yi Shen
Overview
Explore the profile of Shu Yi Shen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishak C, Marhon S, Tchrakian N, Hodgson A, Loo Yau H, Gonzaga I, et al.
Cancer Discov
. 2025 Jan;
PMID: 39776167
Epigenetic therapies facilitate transcription of immunogenic repetitive elements that cull cancer cells through 'viral mimicry' responses. Paradoxically, cancer-initiating events also facilitate transcription of repetitive elements. Contributions of repetitive element transcription...
2.
Viner C, Ishak C, Johnson J, Walker N, Shi H, Sjoberg-Herrera M, et al.
Genome Biol
. 2024 Jan;
25(1):11.
PMID: 38191487
Background: Transcription factors bind DNA in specific sequence contexts. In addition to distinguishing one nucleobase from another, some transcription factors can distinguish between unmodified and modified bases. Current models of...
3.
Medina T, Murison A, Smith M, Kinker G, Chakravarthy A, Vitiello G, et al.
Front Immunol
. 2023 Aug;
14:1161901.
PMID: 37600767
Introduction: The imbalance between Th17 and regulatory T cells in inflammatory bowel diseases (IBD) promotes intestinal epithelial cell damage. In this scenario, T helper cell lineage commitment is accompanied by...
4.
Zuccato J, Patil V, Mansouri S, Voisin M, Chakravarthy A, Shen S, et al.
Neuro Oncol
. 2022 Dec;
25(8):1452-1460.
PMID: 36455236
Background: Resolving the differential diagnosis between brain metastases (BM), glioblastomas (GBM), and central nervous system lymphomas (CNSL) is an important dilemma for the clinical management of the main three intra-axial...
5.
Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, et al.
Nat Commun
. 2022 Oct;
13(1):6467.
PMID: 36309516
Metastatic prostate cancer remains a major clinical challenge and metastatic lesions are highly heterogeneous and difficult to biopsy. Liquid biopsy provides opportunities to gain insights into the underlying biology. Here,...
6.
Wilson S, Shen S, Harmon L, Burgener J, Triche Jr T, Bratman S, et al.
Cell Rep Methods
. 2022 Sep;
2(9):100294.
PMID: 36160046
Cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) identifies genomic regions with DNA methylation, using a protocol adapted to work with low-input DNA samples and with cell-free DNA (cfDNA). We developed a...
7.
Burgener J, Zou J, Zhao Z, Zheng Y, Shen S, Huang S, et al.
Clin Cancer Res
. 2021 Jun;
27(15):4230-4244.
PMID: 34158359
Purpose: Circulating tumor DNA (ctDNA) enables personalized treatment strategies in oncology by providing a noninvasive source of clinical biomarkers. In patients with low ctDNA abundance, tumor-naïve methods are needed to...
8.
Loo Yau H, Bell E, Ettayebi I, Campos de Almeida F, Boukhaled G, Shen S, et al.
Mol Cell
. 2021 Feb;
81(7):1469-1483.e8.
PMID: 33609448
We demonstrate that DNA hypomethylating agent (HMA) treatment can directly modulate the anti-tumor response and effector function of CD8 T cells. In vivo HMA treatment promotes CD8 T cell tumor...
9.
Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes
Nuzzo P, Berchuck J, Korthauer K, Spisak S, Nassar A, Abou Alaiwi S, et al.
Nat Med
. 2020 Sep;
26(10):1663.
PMID: 32895574
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
10.
Peter M, Bilenky M, Isserlin R, Bader G, Shen S, De Carvalho D, et al.
Epigenomics
. 2020 Sep;
12(15):1317-1332.
PMID: 32867540
We examined methylation changes in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC) during treatment. Genome-wide methylation analysis of sequentially collected cfDNA samples derived from mCRPC patients undergoing androgen-targeting...